Blockchain Registration Transaction Record

LIXTE’s LB-100 Targets Precision Oncology: Enhancing Chemo & Reducing Side Effects

LIXTE Biotechnology Holdings (LIXT) advances precision oncology with LB-100, a PP2A inhibitor enhancing chemo/radiation. Learn about its novel activation lethality approach and clinical trials. Read more.

This news matters because LIXTE’s LB-100 could significantly improve cancer treatment outcomes by making existing therapies more effective and less toxic, potentially benefiting millions of patients. As a novel PP2A inhibitor in a new field of cancer biology, it represents a paradigm shift that may lead to better survival rates and quality of life. For investors, LIXTE’s clinical progress and patent protection offer a compelling opportunity in the precision oncology space.